HIG:CA:TSX-Global Healthcare Income & Growth Fund (CAD)

FUND | Asset Management |

Last Closing

CAD 8.28

Change

-0.02 (-0.24)%

Market Cap

CAD 0.05B

Volume

102.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Asset Management

Symbol Name Price(Change) Market Cap
BN:CA Brookfield Corporation

-0.07 (-0.09%)

CAD 121.77B
BAM:CA Brookfield Asset Management Lt..

-0.12 (-0.15%)

CAD 33.30B
PHYS:CA Sprott Physical Gold Trust

-0.07 (-0.25%)

CAD 11.82B
IGM:CA IGM Financial Inc.

-0.64 (-1.41%)

CAD 10.51B
ONEX:CA Onex Corp

-0.82 (-0.71%)

CAD 8.46B
PSLV:CA Sprott Physical Silver

-0.20 (-1.38%)

CAD 7.54B
CEF:CA Sprott Physical Gold and Silve..

-0.21 (-0.63%)

CAD 6.78B
CIX:CA CI Financial Corp

-0.04 (-0.17%)

CAD 3.40B
BBUC:CA Brookfield Business Corp

-0.32 (-0.86%)

CAD 2.73B
FIH-U:CA Fairfax India Holdings Corpora..

-0.04 (-0.25%)

CAD 2.20B

ETFs Containing HIG:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Asset Management) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.73% 14% F 23% F
Dividend Return 6.69% 63% D 87% B+
Total Return 7.42% 22% F 33% F
Trailing 12 Months  
Capital Gain 4.28% 16% F 24% F
Dividend Return 8.31% 63% D 87% B+
Total Return 12.59% 22% F 34% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.48% 22% F 23% F
Dividend Return -1.42% 14% F 17% F
Total Return 0.05% 5% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 10.94% 74% C 69% C-
Risk Adjusted Return -13.00% 18% F 18% F
Market Capitalization 0.05B 22% F 25% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.